SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as geopolitical tensions escalate, driving the U.S. and its allies to aggressively pursue strategies for diversifying critical mineral supply chains away from China, including discussions around securing rare earth sources. The community is keenly focused on MP's strategic position as a vertically integrated domestic rare earth producer, with ongoing conversations about significant government-backed initiatives and partnerships with major tech companies fueling bullish sentiment despite concerns over market manipulation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors anticipate its optical interposer technology will be critical for next-generation AI data centers, fueled by strategic partnerships with industry giants like Luxshare and Foxconn that indirectly support hyperscalers like Meta and NVIDIA. The community is buzzing about POET's patented passive alignment process, which promises to revolutionize high-volume optical module manufacturing by enabling superior speed and energy efficiency over traditional copper. While eagerly awaiting official news, the market speculates on significant production orders ramping up by 2026, positioning POET as a potential leader in the rapidly expanding photonics sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, which significantly de-risks the regulatory pathway for sonelokimab in hidradenitis suppurativa by allowing reliance on existing trial data for BLA submission. This development has fueled widespread community speculation around potential acquisition bids from major pharmaceutical companies like Merck and Eli Lilly, intensifying discussions about the drug's long-term value and multi-indication potential.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is currently trending due to high anticipation for upcoming announcements regarding its role in powering next-generation AI data centers with GaN and SiC technology, especially in collaboration with NVIDIA's 800V architecture. The community is actively discussing the stock's substantial short interest, leading to widespread speculation of a significant short squeeze and potential technical breakout.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

MELANIA CRYPTO is trending amidst community debate, with recent token supply releases noted by investors contributing to price fluctuations. While some anticipate a rebound driven by potential catalysts like an upcoming movie, a significant portion of the community views the asset as a "scam" or "pump and dump" within the broader political meme coin landscape, citing substantial losses and continued token distribution as key concerns.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following news that it is fully funded for Q1-2026 with zero debt and a significant credit line from a single investor, alongside its breakthrough molecular-level tracking technology for anti-counterfeiting. The community is actively discussing the extremely low float and high short interest, speculating on a potential 'infinity squeeze' with many anticipating substantial upward movement.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to robust community excitement over a recent pre-production defense order, which validates its rugged AI edge compute technology for military vehicles. Investors are actively discussing the potential for much larger follow-on contracts, alongside the company's strategic pivot to high-margin opportunities, a strengthened balance sheet, and an exceptionally low share float. This confluence of factors is generating significant speculation about the stock's future momentum in the defense and AI sectors.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd is trending due to intense community discussion around its ultra-low share float and significant short interest, leading to strong speculation about a potential short squeeze. Traders are keenly drawing comparisons to past high-volatility runners, with sentiment further fueled by its presence on the Reg SHO list and anticipation of upcoming earnings and contract news for its Hong Kong-based security and AI solutions.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is seeing intense trading volume and significant volatility after releasing interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, which showed encouraging mucus plug reduction but limited lung function improvement, leading to a sharp sell-off. The community is debating whether this represents an overreaction and a buying opportunity, given the drug's biological activity and potential for higher doses, or if it signals deeper concerns about the company's valuation and delayed regulatory submissions for other programs. Further discussions revolve around high short interest and a pending trade secret lawsuit, intensifying the stock's unpredictable movements.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg Commerce is trending amidst widespread community belief that aggressive insider buying has drastically reduced the public float. This tight share availability, coupled with allegations of persistent market manipulation and rising short interest, is driving intense discussion about a potential significant short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low after the company announced a significant setback for its lead drug candidate, AK006.The biotech company revealed it would cease further clinical development of AK006 after its preclinical inhibitory effects failed to translate into clinical benefits for patients with chronic spontaneous urticaria (CSU).In the proof-of-concept trial, 34 adult patients with moderate-to-severe CSU refractory to antihistamines, with or without prior omalizumab exposure, were randomized 2:1 to receive AK006 or placebo.&nbsp;The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.&nbsp;The company will retain a small team of about 15 employees to explore strategic alternatives, ensure compliance, and oversee the wind-down of its phase 1 trial.Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025.&nbsp;The company estimates its cash reserves will decline to $35–$40 million by June 30, 2025.Following the announcement, several analysts adjusted their outlook on Allakos, according to The Fly.Piper Sandler downgraded the stock to ‘Neutral’ from ‘Overweight,’ slashing its price target to $0.30 from $7. The brokerage noted AK006 was Allakos’s sole asset, leaving the remaining valuation restricted to cash.JMP Securities downgraded Allakos to ‘Market Perform’ from ‘Outperform’.On Stocktwits, sentiment for Allakos shifted sharply to ‘bearish’ as disappointed retail investors voiced their concerns.&nbsp;<stembedurl>https://stocktwits.com/Majlo97/message/601635808</stembedurl><stembedurl>https://stocktwits.com/subieroo_wrx/message/601634053</stembedurl>Data showed declining interest in the stock, with a 4.6% drop in followers over the past year and a 44% reduction in message volume last week.<a href="https://stocktwits.com/symbol/ALLK">Allakos stock</a> has now lost 77% over the past 12 months, reflecting mounting challenges for the small-cap biotech as it faces an uncertain future.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Equity

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Allakos Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

ALLK
Allakos Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALLK News

ALLKAllakos Inc